AUPR951501A0 - Modified sustained release pharmaceutical system - Google Patents

Modified sustained release pharmaceutical system

Info

Publication number
AUPR951501A0
AUPR951501A0 AUPR9515A AUPR951501A AUPR951501A0 AU PR951501 A0 AUPR951501 A0 AU PR951501A0 AU PR9515 A AUPR9515 A AU PR9515A AU PR951501 A AUPR951501 A AU PR951501A AU PR951501 A0 AUPR951501 A0 AU PR951501A0
Authority
AU
Australia
Prior art keywords
sustained release
release pharmaceutical
pharmaceutical system
modified sustained
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPR9515A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Smart Drug Systems Inc
Original Assignee
CASTELLA RES Pty Ltd
CASTELLA RESEARCH PTY Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CASTELLA RES Pty Ltd, CASTELLA RESEARCH PTY Ltd filed Critical CASTELLA RES Pty Ltd
Priority to AUPR9515A priority Critical patent/AUPR951501A0/en
Publication of AUPR951501A0 publication Critical patent/AUPR951501A0/en
Assigned to SMART DRUG SYSTEMS INC reassignment SMART DRUG SYSTEMS INC Alteration of Name(s) of Applicant(s) under S113 Assignors: Castella Research Pty Ltd
Assigned to SMART DRUG SYSTEMS INC reassignment SMART DRUG SYSTEMS INC Assignment by Applicant under S 113 Assignors: Castella Research Pty Ltd
Priority to EP02804837A priority patent/EP1453482A4/en
Priority to BR0214159-0A priority patent/BR0214159A/pt
Priority to NZ532378A priority patent/NZ532378A/en
Priority to PCT/AU2002/001661 priority patent/WO2003051335A1/en
Priority to US10/495,642 priority patent/US20050063907A1/en
Priority to CNA028228111A priority patent/CN1589133A/zh
Priority to JP2003552268A priority patent/JP2005517653A/ja
Priority to AU2002366248A priority patent/AU2002366248A1/en
Priority to CA002468986A priority patent/CA2468986A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AUPR9515A 2001-12-14 2001-12-14 Modified sustained release pharmaceutical system Abandoned AUPR951501A0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AUPR9515A AUPR951501A0 (en) 2001-12-14 2001-12-14 Modified sustained release pharmaceutical system
CA002468986A CA2468986A1 (en) 2001-12-14 2002-12-09 Radioopaque sustained release pharmaceutical system
AU2002366248A AU2002366248A1 (en) 2001-12-14 2002-12-09 Radioopaque sustained release pharmaceutical system
JP2003552268A JP2005517653A (ja) 2001-12-14 2002-12-09 X線不透過性徐放性医薬器具
BR0214159-0A BR0214159A (pt) 2001-12-14 2002-12-09 Sistema farmacêutico radiopaco de liberação prolongada
EP02804837A EP1453482A4 (en) 2001-12-14 2002-12-09 RADIOOPAQUE PHARMACEUTICAL SYSTEM WITH PROLONGED RELEASE
NZ532378A NZ532378A (en) 2001-12-14 2002-12-09 Radio-opaque sustained release delivery apparatus made from biodegradable and/or biocompatible materials for implant into a living body to deliver pharmaceutically active components
PCT/AU2002/001661 WO2003051335A1 (en) 2001-12-14 2002-12-09 Radioopaque sustained release pharmaceutical system
US10/495,642 US20050063907A1 (en) 2001-12-14 2002-12-09 Radioopaque sustained release pharmaceutical system
CNA028228111A CN1589133A (zh) 2001-12-14 2002-12-09 不透射线的缓释药物系统

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPR9515A AUPR951501A0 (en) 2001-12-14 2001-12-14 Modified sustained release pharmaceutical system

Publications (1)

Publication Number Publication Date
AUPR951501A0 true AUPR951501A0 (en) 2002-01-24

Family

ID=3833131

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPR9515A Abandoned AUPR951501A0 (en) 2001-12-14 2001-12-14 Modified sustained release pharmaceutical system

Country Status (9)

Country Link
US (1) US20050063907A1 (cg-RX-API-DMAC7.html)
EP (1) EP1453482A4 (cg-RX-API-DMAC7.html)
JP (1) JP2005517653A (cg-RX-API-DMAC7.html)
CN (1) CN1589133A (cg-RX-API-DMAC7.html)
AU (1) AUPR951501A0 (cg-RX-API-DMAC7.html)
BR (1) BR0214159A (cg-RX-API-DMAC7.html)
CA (1) CA2468986A1 (cg-RX-API-DMAC7.html)
NZ (1) NZ532378A (cg-RX-API-DMAC7.html)
WO (1) WO2003051335A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
JP2006500115A (ja) 2000-11-16 2006-01-05 マイクロスフエリツクス・エル・エル・シー 密封小線源治療用の可撓性および/または弾性シードまたはストランド
CN1638747A (zh) * 2002-01-24 2005-07-13 斯玛特药物系统公司 持续释放药物组合物
US8920826B2 (en) * 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
PL1696822T3 (pl) * 2003-11-13 2010-08-31 Psivida Inc Wstrzykiwane implanty o opóźnionym wydzielaniu mające matrycę rdzenia i powłokę podatne na erozję biologiczną
TWI434676B (zh) 2004-03-19 2014-04-21 Merck Sharp & Dohme 可用x射線看出之藥物遞送裝置
DE102006021016A1 (de) * 2006-05-05 2007-11-15 Dürschinger, Günter Chemisch aktivierbare Kapsel für die Durchgangsprüfung und Behandlung des Darm-Trakts
US8475823B2 (en) * 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US8956642B2 (en) * 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US20100203102A1 (en) * 2009-02-10 2010-08-12 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using bupivacaine and an anti-onflammatory agent
CN102355891A (zh) * 2009-03-17 2012-02-15 英特威国际有限公司 大环内酯药物递送系统
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
WO2016204026A1 (ja) * 2015-06-15 2016-12-22 seven dreamers laboratories株式会社 鼻腔留置デバイス
US11096781B2 (en) 2016-08-01 2021-08-24 Edwards Lifesciences Corporation Prosthetic heart valve
WO2018067882A1 (en) 2016-10-05 2018-04-12 Titan Pharmaceuticals, Inc. Implantable devices for drug delivery with reduced burst release
CA3199943A1 (en) 2020-08-24 2022-03-03 Edwards Lifesciences Corporation Balloon cover for a delivery apparatus for an expandable prosthetic heart valve

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD205069A1 (de) * 1982-04-14 1983-12-21 Univ Ernst Moritz Arndt Verfahren zur herstellung eines therapeutischen mittels
US4866132A (en) * 1986-04-17 1989-09-12 The Research Foundation Of State University Of New York Novel radiopaque barium polymer complexes, compositions of matter and articles prepared therefrom
ES2038669T3 (es) * 1986-09-18 1993-08-01 London School Of Pharmacy Innovations Ltd Formulacion farmaceutica.
ATE108651T1 (de) * 1988-05-20 1994-08-15 Liposome Co Inc Aktives mittel: lipid-komplex mit hohem verhältnis.
GB9204918D0 (en) * 1992-03-06 1992-04-22 Nycomed As Chemical compounds
US5674468A (en) * 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
CZ284844B6 (cs) * 1992-03-06 1999-03-17 Nycomed Imaging A/S Kontrastní prostředek a způsob jeho výroby
JP3720386B2 (ja) * 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
CN1168640A (zh) * 1994-08-17 1997-12-24 波士顿科技公司 植入体、植入方法和施放装置
AU716005B2 (en) * 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
UA54505C2 (uk) * 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Полімери, що біологічно розкладаються, зшиті фосфатами, композиції, вироби і способи для їх виготовлення і використання
EP0938894A1 (en) * 1998-02-16 1999-09-01 Biomat B.V. Implantable radiopaque device and use thereof
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
US6599448B1 (en) * 2000-05-10 2003-07-29 Hydromer, Inc. Radio-opaque polymeric compositions

Also Published As

Publication number Publication date
NZ532378A (en) 2005-02-25
JP2005517653A (ja) 2005-06-16
BR0214159A (pt) 2004-09-28
EP1453482A4 (en) 2006-09-20
EP1453482A1 (en) 2004-09-08
US20050063907A1 (en) 2005-03-24
WO2003051335A1 (en) 2003-06-26
CN1589133A (zh) 2005-03-02
CA2468986A1 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
AU2002258563A1 (en) Pharmaceutical formulations for sustained release
AU2002327068A1 (en) Immediate release tablet
AU2002348242A1 (en) Medication adherence system
AUPR602401A0 (en) Sustained release delivery system
AU2002326933A1 (en) Plasmatron-catalyst system
AU2002364006A1 (en) Micro-rotocraft surveillance system
AU2003233084A1 (en) Alerting system
AU2002311905A1 (en) Global compliance system
AUPR602501A0 (en) Sustained release pharmaceutical composition
AU2002337803A1 (en) Sustained release pharmaceutical compositions
AU2001283359A1 (en) Drug release (delivery system)
AU2002343555A1 (en) Eutectic-based self-nanoemulsified drug delivery system
AU2002345340A1 (en) Magneto-massage system
AU2002324286A1 (en) Distributed event notification system
EP1453482A4 (en) RADIOOPAQUE PHARMACEUTICAL SYSTEM WITH PROLONGED RELEASE
PL374280A1 (en) Soluble drug extended release system
AU2002333276A1 (en) Drugs for vasculopaties
AU2002241758A1 (en) Drug screening system
AU2002351380A1 (en) Bookview system
AU2002329204A1 (en) Pharmaceutical detailing system
AUPS155402A0 (en) Administration system
AU2002329408A1 (en) Distributed system architecture
AUPR807001A0 (en) Order system
AU2001288201A1 (en) Emergency system
AU2002323447A1 (en) Sustained release preparations

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SMART DRUG SYSTEMS INC

Free format text: THE FORMER OWNER WAS: CASTELLA RESEARCH PTY LTD